These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 18775469)
1. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors. Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469 [TBL] [Abstract][Full Text] [Related]
2. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3. Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604 [TBL] [Abstract][Full Text] [Related]
3. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3). Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334 [TBL] [Abstract][Full Text] [Related]
4. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3). Lota RK; Dhanani S; Owen CP; Ahmed S Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984 [TBL] [Abstract][Full Text] [Related]
5. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791 [TBL] [Abstract][Full Text] [Related]
6. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3. Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902 [TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure. Karkola S; Alho-Richmond S; Wahala K Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344 [TBL] [Abstract][Full Text] [Related]
8. Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3. Vicker N; Bailey HV; Day JM; Mahon MF; Smith A; Tutill HJ; Purohit A; Potter BVL Molecules; 2021 Nov; 26(23):. PubMed ID: 34885749 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529 [TBL] [Abstract][Full Text] [Related]
10. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708 [TBL] [Abstract][Full Text] [Related]
11. The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals. Nashev LG; Schuster D; Laggner C; Sodha S; Langer T; Wolber G; Odermatt A Biochem Pharmacol; 2010 Apr; 79(8):1189-99. PubMed ID: 20005209 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762 [TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis and in vitro characterization of potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors based on 2-substitutions of estrone and D-homo-estrone. Möller G; Deluca D; Gege C; Rosinus A; Kowalik D; Peters O; Droescher P; Elger W; Adamski J; Hillisch A Bioorg Med Chem Lett; 2009 Dec; 19(23):6740-4. PubMed ID: 19836949 [TBL] [Abstract][Full Text] [Related]
14. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760 [TBL] [Abstract][Full Text] [Related]
15. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Maltais R; Fournier MA; Poirier D Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247 [TBL] [Abstract][Full Text] [Related]
16. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking. Karkola S; Lilienkampf A; Wähälä K ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances. Zhao B; Hu GX; Chu Y; Jin X; Gong S; Akingbemi BT; Zhang Z; Zirkin BR; Ge RS Chem Biol Interact; 2010 Oct; 188(1):38-43. PubMed ID: 20619251 [TBL] [Abstract][Full Text] [Related]
18. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892 [TBL] [Abstract][Full Text] [Related]
19. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812 [TBL] [Abstract][Full Text] [Related]
20. Curcumin derivatives inhibit testicular 17beta-hydroxysteroid dehydrogenase 3. Hu GX; Liang G; Chu Y; Li X; Lian QQ; Lin H; He Y; Huang Y; Hardy DO; Ge RS Bioorg Med Chem Lett; 2010 Apr; 20(8):2549-51. PubMed ID: 20346654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]